Anti-inflammatory effect of telmisartan in patients with hypertension

Anti-inflammatory effect of telmisartan in patients with hypertension - Anti-inflammatory effect of telmisartan in patients with hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009186

Enrollment

Registered

2012-11-01

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

telmisartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Uncontorable hypertension(SBP>130mmHg or DBP>110mmHg) (2)Patients whose serum creatinine does not rise rapidly (3)Patients who do not take the renin-angiotensin system inhibitor (4)Ambulant patient (5)Patients of 20 years and upward

Exclusion criteria

Exclusion criteria: (1)Allergy against telmisartan (2)Secondary hyperuricemia (3)Systolic BP > 180mmHg, or diastolic BP > 110mmHg (4)Patients with ALT or AST more than twice (5)History of cardiovascular disease and stroke in the previous 6 months. (6)Pregnant women (7)Patients who are not recommended for participation in this study by physician in charge with medical reasons

Design outcomes

Primary

Measure	Time frame
The levels of blood pressure, blood/urinary sTNFRs, TNFalpha, OPG, Osteopontin, hs-CRP, IL-6 and MCP-1	—

Secondary

Measure	Time frame
The levels of BW, BMI, e-GFR, albuminuria, serum lipid(TC/TG/HDL-C), and HbA1c	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026